Lower Placebo Responses After Long-Term Exposure to Fibromyalgia Pain

Area of Science:

• Neuroscience
• Pain Management
• Clinical Trials

Background:

• Fibromyalgia syndrome (FM) involves central pain inhibition dysfunction.
• Placebo analgesia activates endogenous pain inhibition pathways.
• Knowledge regarding placebo mechanisms in chronic pain patients is limited.

Purpose of the Study:

• To investigate the effect of fibromyalgia duration on placebo response.
• To examine how long-term fibromyalgia pain exposure influences central pain inhibition.
• To understand the implications for placebo-controlled trial interpretations.

Main Methods:

• Analysis of the placebo group (n=37) from a 12-week randomized trial.
• Classification of patients into placebo responders and non-responders.
• Assessment of pressure pain sensitivity, clinical pain, and FM impact.

Main Results:

• Longer FM duration correlated with reduced placebo analgesia in responders (r=.689, P=.004).
• Fibromyalgia duration negatively impacts pain levels and placebo-induced pain relief.
• No significant association found between FM duration and placebo response in non-responders (r=-.348, P=.112).

Conclusions:

• Fibromyalgia duration significantly influences endogenous pain regulation.
• Early intervention in FM may preserve the capacity for endogenous pain modulation.
• Consideration of disease duration is vital when interpreting placebo-controlled trial results in FM.